Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade®) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC)-Reference-Cited by-同舟云学术

Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade®) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC)

Published:2010-04 Issue:1 Volume:68 Page:89-93
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Li Tianhong,Ho Liawaty,Piperdi Bilal,Elrafei Tarek,Camacho Fernando J.,Rigas James R.,Perez-Soler Roman,Gucalp Rasim

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference27 articles.

1. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer;Schiller;N Engl J Med,2002

2. Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials;Pujol;Lung Cancer,2006

3. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer;Sandler;N Engl J Med,2006

4. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil;Reck;J Clin Oncol,2009

5. BO17704 (AVAIL): a phase III randomized study of first-line bevacizumab combined with cisplatin/gemcitabine (CG) in patients with advanced or recurrent nonsquamous, non-small-cell lung cancer (NSCLC);Manegold,2008

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Autophagy and oxidative stress modulation mediate Bortezomib resistance in prostate cancer;PLOS ONE;2024-02-27

2. Proteasome inhibitors in the treatment of nonsmall cell lung cancer: A systematic review of clinical evidence;Health Science Reports;2023-11

3. miR-466 Contributes to the Enhanced Antitumor Effect of Bortezomib on Non-Small-Cell Lung Cancer by Inhibiting CCND1;Chemotherapy;2022

4. Proteasomes and Ubiquitin;Encyclopedia of Respiratory Medicine;2022

5. Luminescent core–shell Ca2MoO5:Eu3+-MCM-41 structure for sustained drug release;Materials Today Chemistry;2021-12